Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer

Future Oncology
Despina Handolias, Grant A McArthur

Abstract

Cancer literature has consistently described autocrine loops involving growth factors to be important mechanisms for cellular transformation and proliferation in preclinical cancer models. Finally, convincing clinical data exist to implicate autocrine loops as central to the pathogenesis of a malignant condition, largely as a result of the recent development of inhibitors of protein tyrosine kinases important in cell signaling and growth. Although a rare condition, the study of patients with dermatofibrosarcoma protuberans (DFSP) is enriched by data demonstrating strong scientific rationale for its pathogenesis and susceptibility to molecular-based therapies. DFSP is a low-grade sarcoma that responds to treatment with imatinib, an inhibitor of the PDGF receptor tyrosine kinase. This treatment response illustrates the importance of autocrine/paracrine loops involving PDGF and its receptor as the key molecular target in DFSP. New insight into this fundamental biological mechanism sets the scene for the further development of molecular-targeted therapeutic options for cancer.

References

Feb 1, 1990·Journal of Neuro-oncology·G R HarshL T Williams
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·T P FlemingS A Aaronson
Feb 6, 1985·Nature·M B Sporn, A B Roberts
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H SuitA E Rosenberg
Sep 1, 1996·Journal of the American Academy of Dermatology·H M Gloster
Dec 4, 2003·International Journal of Cancer. Journal International Du Cancer·Stefania BeniniKatia Scotlandi
Mar 17, 2004·Seminars in Cancer Biology·Arthur M MercurioJun Chung
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grant A McArthurJonathan A Fletcher
Jul 15, 2005·The New England Journal of Medicine·Daniela S Krause, Richard A Van Etten
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco FioreAlessandro Gronchi
Jan 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Robert B WestMatt van de Rijn
Feb 9, 2006·British Journal of Cancer·P H PatelR J Motzer
Jun 3, 2006·The Journal of Clinical Investigation·Martin JechlingerStefan Grünert
Aug 17, 2006·Cancer Research·Anna ErlandssonKarin Forsberg-Nilsson
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J Motzer, Ronald M Bukowski

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Dermatologic Clinics
Hillary Johnson-Jahangir, Désirée Ratner
Biologics : Targets & Therapy
Stefanos V Labropoulos, Evangelia D Razis
Hematology/oncology Clinics of North America
Farhad Ravandi, Partow Kebriaei
AJR. American Journal of Roentgenology
Pedro Javier Bustillo BusalacchiSilvia Torres Del Río
© 2022 Meta ULC. All rights reserved